139 related articles for article (PubMed ID: 36347999)
1. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India.
Palani HK; Arunachalam AK; Yasar M; Venkatraman A; Kulkarni U; Lionel SA; Selvarajan S; Korula A; Abraham A; George B; Adair JE; Orentas R; Dropulic B; Mathews V
Bone Marrow Transplant; 2023 Feb; 58(2):160-167. PubMed ID: 36347999
[TBL] [Abstract][Full Text] [Related]
2. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M
Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403
[TBL] [Abstract][Full Text] [Related]
3. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system.
Zhang W; Jordan KR; Schulte B; Purev E
Drug Des Devel Ther; 2018; 12():3343-3356. PubMed ID: 30323566
[TBL] [Abstract][Full Text] [Related]
4. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
5. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
6. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
Front Immunol; 2020; 11():482. PubMed ID: 32528460
[TBL] [Abstract][Full Text] [Related]
7. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
Mock U; Nickolay L; Philip B; Cheung GW; Zhan H; Johnston ICD; Kaiser AD; Peggs K; Pule M; Thrasher AJ; Qasim W
Cytotherapy; 2016 Aug; 18(8):1002-1011. PubMed ID: 27378344
[TBL] [Abstract][Full Text] [Related]
8. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.
Kekre N; Hay KA; Webb JR; Mallick R; Balasundaram M; Sigrist MK; Clement AM; Nielsen JS; Quizi J; Yung E; Brown SD; Dreolini L; Waller DD; Smazynski J; Gierc NS; Loveless BC; Clark K; Dyer T; Hogg R; McCormick L; Gignac M; Bell S; Chapman DM; Bond D; Yong S; Fung R; Lockyer HM; Hodgson V; Murphy C; Subramanian A; Wiebe E; Yoganathan P; Medynski L; Vaillan DC; Black A; McDiarmid S; Kennah M; Hamelin L; Song K; Narayanan S; Rodrigo JA; Dupont S; Hawrysh T; Presseau J; Thavorn K; Lalu MM; Fergusson DA; Bell JC; Atkins H; Nelson BH; Holt RA
Front Immunol; 2022; 13():1074740. PubMed ID: 36601119
[TBL] [Abstract][Full Text] [Related]
9. Automated, scaled, transposon-based production of CAR T cells.
Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530
[TBL] [Abstract][Full Text] [Related]
10. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Palen K; Zurko J; Johnson BD; Hari P; Shah NN
Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
12. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
14. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
[TBL] [Abstract][Full Text] [Related]
15. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing chimeric antigen receptor T cells: issues and challenges.
Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
[TBL] [Abstract][Full Text] [Related]
17. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
19. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
